Actively Recruiting
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Led by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Updated on 2026-04-21
42
Participants Needed
11
Research Sites
154 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.
CONDITIONS
Official Title
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects voluntarily joined this study, signed the informed consent form, and had good compliance
- Age between 18 and 75 years
- Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0-1
- Expected survival longer than 12 weeks
- Histologically or cytologically diagnosed with advanced non-squamous non-small cell lung cancer
- Have received standard treatment or lack effective treatment if in the monotherapy introduction stage
- Have at least one measurable lesion within the radiotherapy area classified as progressive by RECIST 1.1 criteria
- Major organs are functioning well
- Female and male subjects of childbearing potential agree to use contraception during the study and for 6 months after study end
You will not qualify if you...
- Presence of other malignancies within 5 years prior to first dose
- Adverse reactions from previous anti-tumor treatments not recovered to grade 1 CTCAE 5.0 or below at treatment start
- Major surgery within 4 weeks prior to study or expected during treatment, or long-term unhealed wounds or fractures
- Hyperactive or venous thrombosis events within 6 months before first administration
- Major cardiovascular diseases
- Active hepatitis
- History of psychotropic drug abuse or inability to quit or mental disorders
- Active infection with grade 2 or higher CTCAE 5.0 within 2 weeks before first administration
- Renal failure requiring dialysis
- History of immune deficiency
- Epilepsy requiring treatment
- History or evidence of interstitial lung disease or radiation pneumonitis needing steroids
- Participation in other anti-tumor clinical trials within 4 weeks before first treatment
- Pregnant or lactating women
- Serious or uncontrolled systemic diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
2
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
3
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Not Yet Recruiting
4
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Not Yet Recruiting
5
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China, 210008
Actively Recruiting
6
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Actively Recruiting
7
Affiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning, China, 116001
Actively Recruiting
8
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
9
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
10
West China hospital, Sichuan University
Chengdu, Sichuan, China, 610041
Not Yet Recruiting
11
Chengdu Third People's Hospital
Chengdu, Sichuan, China, 610100
Not Yet Recruiting
Research Team
L
Li Zhang, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here